Corvus Pharma (CRVS) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- S&P 500, Dow hit record highs on strong AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 11, 2021 4:01 PM ESTBURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less underwriting discounts and commissions. The offering is... More
